Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 77137, held by Cipla. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 77137 (Terbinafine Hydrochloride), held by Cipla, was first approved by FDA on Jul 2, 2007, with 4 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. Terbinafine tablets are an allylamine antifungal
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Aug 9, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 9, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 9, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jan 10, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters